Boronic acid derivatives

1. A compound of formula (I)

wherein:

LX denotes (CH 2 ) n ;

LY denotes (CH 2 ) m ;

X denotes NR 4a COR 4b , CONR 5a R 5b , SO 2 R 6 , SO 2 NR 7a R 7b , SO 2 NHR 8 , SO 2 R 9a NR 9b COR 9c , NR 10a SO 2 R 10b or NHSO 2 R 11 ;

Y denotes a mono- or bicyclic, 5-, 6-, or 9-membered hydrocarbon or heterocycle, each independently from on another unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, CN, R 3a , OR 3a , CONHR 3a , CONR 3b R 3a , CONH 2 , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NHR 3a , N(R 3a ) 2 , (CH 2 ) q —SR 3a , (CH 2 ) q —N(R 3a ) 2 and/or (CH 2 ) q —Z, wherein the monocyclic hydrocarbon system is aromatic and at least one ring of the bicyclic hydrocarbon or heterocycle is aromatic, and wherein the heterocyclic system contains 1, 2 or 3 N and/or O and/or S atoms;

R 1 , R 2 denote H

R 3a , R 3b , R 3c denote each, independently from one another, linear or branched C1-C6-alkyl, wherein 1 to 5 H atoms may be replaced by Hal, OH and/or OAlk;

R 4a , R 4b , R 5a , R 5b , R 6 , R 7a , R 7b , R 8 , R 9a , R 9b , R 9c , R 10a , R 10b and R 11 denote each, independently from one another, Ar1, Het1 or A; or R 5a and R 5b and/or R 7a and R 7b form together a C3-C6-cycloalkyl residue;

A denotes linear or branched C1-C6-alkyl, C3-C6-cycloalkyl, each unsubstituted or mono-, di-, tri- or tetrasubstituted by Hal, CN, R 3a , SR 3a , OR 3a , Ar1, Het1, and/or (CH 2 ) q —Z;

Alk denotes linear or branched C1-C6-alkyl;

Ar1 denotes phenyl, which is unsubstituted, mono-, bi- or trisubstituted by Hal, NO 2 , CN, R 3a , OR 3a , CONHR 3a , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NH 2 , NHR 3a , N(R 3a ) 2 , and/or (CH 2 ) q —Z;

Het1 denotes saturated, unsaturated or aromatic 5- or 6-membered heterocycle having 1 to 4 N, O and/or S atoms, wherein each heterocycle may each be unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, NO 2 , CN, R 3a , OR 3a , CONHR 3a , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NH 2 , NHR 3a , N(R 3a ) 2 , and/or (CH 2 ) q —Z;

Z denotes OH, OR 3a ;

n, q denote each, independently from one another, 1, 2, 3, 4, 5 or 6;

m denotes 0, 1, 2, 3 or 4;

Hal denotes F, Cl, Br or I;

and derivatives, prodrugs, solvates, tautomers or stereoisomers thereof as well as the physiologically acceptable salts of each of the foregoing, including mixtures thereof in all ratios; with the proviso that compound (R)-(2-(benzofuran-3-yl)-1-(2-(N-methylmethylsulfonamido) acetamido)ethyl)boronic acid is excluded.

2. The compound according to claim 1 , wherein Y denotes phenyl, which is unsubstituted, mono-, di- or trisubstituted by Hal, CN, R 3a , OR 3a , CONHR 3a , CONR 3b R 3a , CONH 2 , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NHR 3a , N(R 3a ) 2 , Ar2, Het2, (CH 2 ) q —SR 3a , (CH 2 ) q —N(R 3a ) 2 and/or (CH 2 ) q —Z.

3. The compound according to claim 1 , wherein Y denote 3-, 4-, 2,4-, 3,4-, or 2,3,4-substituted phenyl, wherein the substituents are selected from the group consisting of Hal, CN, R 3a , OR 3a , CONHR 3a , CONR 3b R 3a , CONH 2 , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NHR 3a , N(R 3a ) 2 , (CH 2 ) q —SR 3a , (CH 2 ) q —N(R 3a ) 2 and/or (CH 2 ) q —Z.

4. The compound according to claim 3 , wherein Y denotes 2,4-, 3,4-, or 2,3,4-substituted phenyl, wherein the substituents are selected from the group consisting of Hal, CN, R 3a , OR 3a , CONHR 3a , CONR 3b R 3a , CONH 2 , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NHR 3a , N(R 3a ) 2 , (CH 2 ) q -δR 3a , (CH 2 ) q —N(R 3a ) 2 and/or (CH 2 ) q —Z.

5. The compound according to claim 4 , wherein Y denotes

wherein:

G a denotes, F, Cl, Br, CN, R 3a , OR 3a , CONHR 3a , CONR 3b R 3a , CONH 2 , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NHR 3a , N(R 3a ) 2 , (CH 2 ) q —SR 3a , (CH 2 ) q —N(R 3a ) 2 and/or (CH 2 ) q —Z;

G b denotes H, F, Cl, Br, CN, R 3a , OR 3a , CONHR 3a , CONR 3b R 3a , CONH 2 , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NHR 3a , N(R 3a ) 2 , (CH 2 ) q —SR 3a , (CH 2 ) q —N(R 3 ) 2 and/or (CH 2 ) q —Z;

K a , K b denote each, independently from one another, H, F, Cl, Br, CN, R 3a , OR 3a , CONHR 3a , CONR 3b R 3a , CONH 2 , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NHR 3a , N(R 3a ) 2 (CH 2 ) q —SR 3a , (CH 2 ) q —N(R 3a ) 2 and/or (CH 2 ) q —Z;

R 3a , R 3b and R 3c denote each, independently from one another, linear or branched C1-C3-alkyl, wherein 1 to 5 H atoms may be replaced by F, Cl, OH and OAlk, wherein Alk is methyl or ethyl;

q denotes 1 or 2; and

derivatives, prodrugs, solvates, tautomers or stereoisomers thereof, as well as the physiologically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.

6. The compound according to claim 5 , wherein Y denotes

wherein:

G a denotes F, Cl, Br, CN, R 3a , OR 3a , CONHR 3a , CONR 3b R 3a , CONH 2 , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NHR 3a , N(R 3a ) 2 , (CH 2 ) q —SR 3a , (CH 2 ) q —N(R 3a ) 2 and/or (CH 2 ) q —Z;

G b denotes H, F, Cl, Br, CN, R 3a , OR 3a , CONHR 3a , CONR 3b R 3a , CONH 2 , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NHR 3a , N(R 3a ) 2 , (CH 2 ) q —SR 3a , (CH 2 ) q —N(R 3a ) 2 and/or (CH 2 ) q —Z;

K a , K b denote each, independently from one another, H, F, Cl, Br, CN, R 3a , OR 3a , CONHR 3a , CONR 3b R 3a , CONH 2 , NR 3a COR 3b , SO 2 R 3a , SOR 3a , NHR 3a , N(R 3a ) 2 , (CH 2 ) q —SR 3a , (CH 2 ) q —N(R 3a ) 2 and/or (CH 2 ) q —Z;

R 3a , R 3b and R 3c denote each, independently from one another, linear or branched C1-C3-alkyl, wherein 1 to 5 H atoms may be replaced by F, Cl, OH and OAlk, wherein Alk is methyl or ethyl;

q denotes 1 or 2; and

derivatives, prodrugs, solvates, tautomers or stereoisomers thereof, as well as the physiologically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.

7. The compound according to claim 1 , wherein the stereogenic center at the carbon atom adjacent to the boronic acid residue shows an (R)-configuration.

8. The compound according to claim 1 , said compound being selected from the group consisting of:

[(1R)-1-[3-(N-acetylanilino)propanoylamino]-2-phenyl-ethyl]boronic acid;

[(1R)-1-[3-(N-ethylsulfonylanilino)propanoylamino]-2-(p-tolyl)ethyl]boronic acid;

[(1R)-1-[3-(N-methylsulfonylanilino)propanoylamino]-2-(p-tolyl)ethyl]boronic acid;

[(1R)-1-[3-(benzenesulfonyl)propanoylamino]-2-(benzofuran-3-yl)ethyl]boronic acid;

[(1R)-1-[3-[benzenesulfonyl(ethyl)amino]propanoylamino]-2-(p-tolyl)ethyl]boronic acid;

[(1R)-1-[3-[benzenesulfonyl(isopropyl)amino]propanoylamino]-2-(p-tolyl)ethyl]-boronic acid;

[(1R)-1-[3-[benzenesulfonyl(methyl)amino]propanoylamino]-2-(p-tolyl)ethyl]-boronic acid;

[(1R)-1-[3-[benzoyl(ethyl)amino]propanoylamino]-2-phenyl-ethyl]boronic acid;

[(1R)-1-[3-[benzoyl(isopropyl)amino]propanoylamino]-2-phenyl-ethyl]boronic acid;

[(1R)-1-[3-[benzoyl(methyl)amino]propanoylamino]-2-phenyl-ethyl]boronic acid;

[(1R)-1-[3-[ethyl(ethylsulfonyl)amino]propanoylamino]-2-(p-tolyl)ethyl]boronic acid;

[(1R)-1-[3-[ethyl-(2-methylbenzoyl)amino]propanoyl amino]-2-phenyl-ethyl]boronic acid;

[(1R)-1-[3-[ethyl-(3-methylbenzoyl)amino]propanoylami no]-2-phenyl-ethyl]boronic acid;

[(1R)-1-[3-[ethyl-(4-methylbenzoyl)amino]propanoylamino]-2-phenyl-ethyl]boronic acid;

[(1R)-1-[3-[isopropyl(methylsulfonyl)amino]propanoylamino]-2-(p-tolyl)ethyl]-boronic acid;

[(1R)-1-[[2-[benzenesulfonyl(ethyl)amino]acetyl]amino]-2-(p-tolyl)ethyl]boronic acid;

[(1R)-1-[[2-[benzoyl(ethyl)amino]acetyl]amino]-2-phenyl-ethyl]boronic acid;

[(1R)-1-[[5-(dimethylamino)-5-oxo-pentanoyl]amino]-2-(3-ethylphenyl)ethyl]-boronic acid;

[(1R)-2-(2,4-dimethylphenyl)-1-[3-[ethyl-(4-methylbenzoyl)amino]-propanoylamino]ethyl]boronic acid;

[(1R)-2-(3-ethylphenyl)-1-(3-methylsulfonylpropanoylamino)ethyl]boronic acid;

[(1R)-2-(3-ethylphenyl)-1-(4-methylsulfonylbutanoylamino)ethyl]boronic acid;

[(1R)-2-(3-ethylphenyl)-1-(5-methylsulfonylpentanoylamino)ethyl]boronic acid;

[(1R)-2-(benzofuran-3-yl)-1-(3-methylsulfonylpropanoylamino)ethyl]boronic acid;

[(1R)-2-(2,4-dimethylphenyl)-1-[[2-[ethyl(propanoyl)amino]acetyl]amino]ethyl]-boronic acid;

[(1R)-1-[3-[ethyl-(4-methoxybenzoyl)amino]propanoylamino]-2-(4-fluorophenyl)-ethyl]boronic acid;

[(1R)-1-[3-[(4-chlorobenzoyl)-ethyl-amino]propanoylamino]-2-(4-fluorophenyl)-ethyl]boronic acid;

[(1R)-1-[3-[ethyl-[4-(trifluoromethyl)benzoyl]amino]propanoylamino]-2-(4-fluorophenyl)ethyl]boronic acid;

[(1R)-1-[3-[(4-cyanobenzoyl)-ethyl-amino]propanoylamino]-2-(4-fluorophenyl)-ethyl]boronic acid;

[(1R)-2-(2,4-dimethylphenyl)-1-[[2-[ethyl(o-tolylsulfonyl)amino]acetyl]amino]ethyl]-boronic acid;

[(1R)-2-(2,4-dimethylphenyl)-1-[[2-[ethyl(p-tolylsulfonyl)amino]acetyl]amino]ethyl]-boronic acid;

[(1R)-2-(2,4-dimethylphenyl)-1-[[2-[ethyl(m-tolylsulfonyl)amino]acetyl]amino]ethyl]-boronic acid;

[(1R)-2-(2,4-dimethylphenyl)-1-[[2-[methyl(p-tolylsulfonyl)amino]acetyl]amino]-ethyl]boronic acid;

[(1R)-2-(2,4-dimethylphenyl)-1-[[2-[isopropyl(p-tolylsulfonyl)amino]acetyl]amino]-ethyl]boronic acid;

[(1R)-2-(2,4-dimethylphenyl)-1-[[2-(N-propanoylanilino)acetyl]amino]-ethyl]boronic acid;

[(1R)-1-[[2-[N-(benzenesulfonyl)anilino]acetyl]amino]-2-(2,4-dimethylphenyl)ethyl]-boronic acid;

[(1R)-2-(2,4-dimethylphenyl)-1-[[2-[ethyl-(2-methylsulfanylacetyl)-amino]acetyl]-amino]ethyl]boronic acid;

[(1R)-1-[[2-[(2-chloroacetyl)-ethyl-amino]acetyl]amino]-2-(2,4-dimethylphenyl)-ethyl]boronic acid;

[(1R)-2-(benzo furan-3-yl)-1-[[3-(dimethylamino)-3-oxo-2-phenyl-propanoyl]-amino]ethyl]boronic acid;

[(1R)-1-[[2-(2-fluoro-N-propanoyl-anilino)acetyl]amino]-2-(3-thienyl)ethyl]boronic acid;

[(1R)-1-[[2-[methyl-[2-(trifluoromethyl)benzoyl]amino]acetyl]amino]-2-(3-thienyl)ethyl]boronic acid;

[(1R)-2-[(3S)-2,3-dihydrobenzofuran-3-yl]-1-[[2-[isopropyl(p-tolylsulfonyl)amino]-acetyl]-amino]ethyl]boronic acid;

[(1R)-1-[3-[(4-chlorobenzoyl)-ethyl-amino]propanoylamino]-2-[(3 S)-2,3-dihydrobenzofuran-3-yl]ethyl]boronic acid;

[(1R)-1-[[2-[ethyl(p-tolylsulfonyl)amino]acetyl]amino]-2-(7-methylbenzofuran-3-yl)ethyl]boronic acid; and

derivatives, prodrugs, solvates, tautomers or stereoisomers thereof, as well as the physiologically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.

9. A pharmaceutical composition comprising at least one compound according to claim 1 , or its derivatives, prodrugs, solvates, tautomers or stereoisomers thereof as well as the physiologically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, as active ingredient, together with a pharmaceutically acceptable carrier.

10. The pharmaceutical composition according to claim 9 , said composition further comprises a second active ingredient or its derivatives, prodrugs, solvates, tautomers or stereoisomers thereof as well as the physiologically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein that second active ingredient is other than a compound of formula (I).

11. A kit consisting of separate packs of:

(a) an effective amount of a compound of claim 1 and/or pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios,

and

(b) an effective amount of a further medicament active ingredient.

12. A process for the preparation of compounds of the formula I and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, characterised in that a compound of Formula (III)

is coupled with a compound of Formula (VI)

wherein all residues of formula (III) and formula (IV) are as defined in claim 1 and wherein the obtained compound of Formula (Ib) is subsequently converted into a compound of Formula (Ia), by treatment with HCl, HBr, HI and/or TFA, in the presence or absence of an excess of a small molecular weight boronic acid

13. A method of treating a subject for medical conditions affected by inhibiting LMP7 comprising administering a compound according to claim 1 or its derivatives, prodrugs, solvates, tautomers or stereoisomers thereof as well as the physiologically acceptable salts of each of the foregoing, including mixtures thereof in all ratios to said subject.

14. The method according to claim 13 , wherein said medical condition is an immunoregulatory abnormality or hematological malignancies.

15. The method according to claim 14 , wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of systemic lupus erythematosis, chronic rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), atherosclerosis, scleroderma, autoimmune hepatitis, Sjogren Syndrome, lupus nephritis, glomerulonephritis, Rheumatoid Arthritis, Psoriasis, Myasthenia Gravis, immunoglobulin A nephropathy, Vasculitis, Transplant rejection, Myositis, Henoch-Schönlein purpura and asthma; and wherein the hematological malignancy is a disease selected from the group consisting of Multiple myeloma, chronic lymphoid leukemia, acute myeloid leukemia, and mantle cell lymphoma.